Evidence map›Paper›PMID 33712594›Full record

ArticleNature communications2021

Iron control of erythroid microtubule cytoskeleton as a potential target in treatment of iron-restricted anemia.

Adam N Goldfarb, Katie C Freeman, Ranjit K Sahu, Kamaleldin E Elagib, Maja Holy, Abhinav Arneja, Renata Polanowska-Grabowska, Alejandro A Gru, Zollie White, Shadi Khalil and 5 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. IL-1/MyD88-Dependent G-CSF and IL-6 Secretion Mediates Postburn Anemia.Journal of immunology (Baltimore, Md. : 1950) · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Regulation of Heme Synthesis by Mitochondrial Homeostasis Proteins.Frontiers in cell and developmental biology · 2022
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Adam N GoldfarbDepartment of Pathology, University of Virginia School of Medicine, Charlottesville, VA, USA. ang3x@virginia.edu.ORCID 0000-0001-9953-2012
Katie C FreemanDepartment of Pathology, University of Virginia School of Medicine, Charlottesville, VA, USA.
Ranjit K SahuDepartment of Pathology, University of Virginia School of Medicine, Charlottesville, VA, USA.
Kamaleldin E ElagibDepartment of Pathology, University of Virginia School of Medicine, Charlottesville, VA, USA.
Maja HolyDepartment of Pathology, University of Virginia School of Medicine, Charlottesville, VA, USA.
Abhinav ArnejaDepartment of Pathology, University of Virginia School of Medicine, Charlottesville, VA, USA.
Renata Polanowska-GrabowskaDepartment of Pharmacology, University of Virginia School of Medicine, Charlottesville, VA, USA.
Alejandro A GruDepartment of Pathology, University of Virginia School of Medicine, Charlottesville, VA, USA.ORCID 0000-0002-2573-8074
Zollie WhiteDepartment of Pathology, University of Virginia School of Medicine, Charlottesville, VA, USA.
Shadi KhalilDepartment of Dermatology, University of California, San Diego School of Medicine, San Diego, CA, USA.
Michael J KerinsDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, CA, USA.
Aikseng OoiDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, CA, USA.
Norbert LeitingerDepartment of Pharmacology, University of Virginia School of Medicine, Charlottesville, VA, USA.
Chance John LuckeyDepartment of Pathology, University of Virginia School of Medicine, Charlottesville, VA, USA.
Lorrie L DelehantyDepartment of Pathology, University of Virginia School of Medicine, Charlottesville, VA, USA.
University of Virginia · USUniversity of Arizona · USUniversity of California San Diego · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1M
Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007267 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GARCIA-BLANCO, MARIANO A. · 1985 to 2024
$13.4M
INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2M
Iron Deficiency: Molecular and Cellular ConsequencesR01DK079924 · NIDDK · UNIVERSITY OF VIRGINIA · PI GOLDFARB, ADAM N. · 2008 to 2023
$5.2M
Targeting Dyrk1a to Promote Donor-independent Platelet ProductionR01HL149667 · NHLBI · UNIVERSITY OF VIRGINIA · PI GOLDFARB, ADAM N. · 2020 to 2023
$2.8M
Validation of Aconitase-Isocitrate Pathway as a Target for Anemia TreatmentR01DK101550 · NIDDK · UNIVERSITY OF VIRGINIA · PI GOLDFARB, ADAM N. · 2016 to 2018
$711k
NCI NIH HHS P30 CA044579NCI NIH HHS T32 CA009109NHLBI NIH HHS R01 HL149667NIAID NIH HHS T32 AI007496NIDDK NIH HHS R01 DK079924NIDDK NIH HHS R01 DK101550NIGMS NIH HHS T32 GM007267
6 · The paper itself

Abstract

Anemias of chronic disease and inflammation (ACDI) result from restricted iron delivery to erythroid progenitors. The current studies reveal an organellar response in erythroid iron restriction consisting of disassembly of the microtubule cytoskeleton and associated Golgi disruption. Isocitrate supplementation, known to abrogate the erythroid iron restriction response, induces reassembly of microtubules and Golgi in iron deprived progenitors. Ferritin, based on proteomic profiles, regulation by iron and isocitrate, and putative interaction with microtubules, is assessed as a candidate mediator. Knockdown of ferritin heavy chain (FTH1) in iron replete progenitors induces microtubule collapse and erythropoietic blockade; conversely, enforced ferritin expression rescues erythroid differentiation under conditions of iron restriction. Fumarate, a known ferritin inducer, synergizes with isocitrate in reversing molecular and cellular defects of iron restriction and in oral remediation of murine anemia. These findings identify a cytoskeletal component of erythroid iron restriction and demonstrate potential for its therapeutic targeting in ACDI.

Indexed as

AnemiaAnimalsCell ProliferationCytoskeletonDisease Models, AnimalErythroid CellsErythropoiesisFemaleFerritinsIronIsocitratesMaleMiceMice, Inbred C57BLMicrotubulesOxidoreductasesFerritinsFth1 protein, mouseIronIsocitratesisocitric acidOxidoreductases

Identifiers

PMID33712594
PMCPMC7955080
OpenAlexW3135351354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.